For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Ziconotide
Illustration for Ziconotide

THE PEPSRADAR ENCYCLOPEDIA

Ziconotide

Specialist intrathecal pain treatment

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Ziconotide · KEY FACTS

Content updated · how dates work

Saved peptides

What is Ziconotide?

Ziconotide is a venom-derived peptide medicine that blocks N-type calcium channels. Its pain research concerns specialist intrathecal delivery, not a generic injectable recovery peptide.

Biological role or research focus

Specialist intrathecal pain treatment.

The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.

Role reference: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Names you may encounter

Prialt

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Venom-derived N-type calcium-channel blocker peptide
Research focus
Specialist intrathecal pain treatment
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Quick answers

Is Ziconotide FDA approved?
Yes. Prialt intrathecal infusion (NDA 021060, approved December 2004) for severe chronic pain. Source ↗
Is Ziconotide safe?
Ziconotide is a non-opioid drug for severe chronic pain, given only by specialists; its boxed warning covers serious psychiatric and neurological effects, and confusion, dizziness and nausea are common. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Ziconotide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Ziconotide refractory-pain randomized trial (2004)Human randomized trial111 patients with refractory pain due to cancer or AIDS, studied at 32 centers.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2004

Ziconotide refractory-pain randomized trial

Did intrathecal ziconotide reduce refractory pain versus placebo?

Population / model
111 patients with refractory pain due to cancer or AIDS, studied at 32 centers.
Study design
Randomized double-blind placebo-controlled intrathecal study with a short titration period and a five-day maintenance phase.
Main finding
Mean visual-analog pain-intensity improvement was 53.1% with ziconotide versus 18.1% with placebo.
Limits & context
The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.

Source: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

13 registered studies name Ziconotide as an intervention; 2 are recruiting or under way, 1 has not started recruiting yet, 7 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy
NCT07499882 · Christian Hospital Northeast Northwest
Not yet recruiting2026-05-0224
OP2C : Prialt® Observatory in Clinical Practice
NCT04321408 · Institut Cancerologie de l'Ouest
Recruiting2020-07-10300
Ziconotide for Non-cancer Pain by Intrathecal Administration
NCT06541184 · ESTEVE Pharmaceuticals SAS
Recruiting2024-10-3085
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
NCT00996983 · National Cancer Institute, Naples
Status unknownPhase 22009-0916
Ziconotide as First-Line IDT
NCT03321955 · Albany Medical College
CompletedPhase 42016-11-0313
Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic
NCT03942848 · Hospices Civils de Lyon
Status unknownPhase 32019-06-2044
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
NCT02268812 · Eisai Limited
Completed2008-04219
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
NCT01992562 · Aaron Boster
WithdrawnPhase 42014-010

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 13 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

The Diagnosis and Treatment of Neuropathic Pain. ↗
Deutsches Arzteblatt international · 2024 Dec 13 · Journal Article, Review
Read available full text ↗

Ziconotide. ↗
· 2006 · Review

The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. ↗
Pharmacological reviews · 2015 Oct · Journal Article, Research Support, Non-U.S. Gov't, Review
Read available full text ↗

Ziconotide. ↗
· 2025 Jan · Study Guide

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Ziconotide is a non-opioid drug for severe chronic pain, given only by specialists; its boxed warning covers serious psychiatric and neurological effects, and confusion, dizziness and nausea are common.

FDA boxed warning

Severe psychiatric symptoms and neurological impairment can occur. It must not be used in people with a history of psychosis, and patients need close watching for confusion, hallucinations, and changes in mood or alertness.

Human safety data: FDA label

Safety is established by FDA labeling from trials in more than a thousand adults with severe chronic pain. Confusion is more common in older adults.

Take extra care with: Blood thinners or bleeding problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • History of psychosis
  • Allergy to ziconotide or any ingredient
  • Conditions that make spinal-canal drug delivery unsafe, such as infection at the site, uncontrolled bleeding or spinal canal blockage

Interactions

  • Opioids delivered into the spinal canal: combination not recommended
  • Sedatives, antiepileptics, neuroleptics or diuretics: higher risk of reduced consciousness
  • Other drugs that depress the nervous system: more dizziness and confusion

Serious risks

  • Hallucinations, paranoia, psychosis and other psychiatric reactions
  • Depression with risk of suicide
  • Memory and thinking problems, reduced alertness or unresponsiveness
  • Meningitis and other infections
  • Raised creatine kinase (a muscle enzyme)

Common side effects

  • dizziness
  • nausea
  • confusion
  • abnormal eye movements (nystagmus)

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Prialt (ziconotide) prescribing information ↗

What the featured evidence can tell us

The complete product information is needed for neurological and other precautions. Intrathecal medicine requires specialist selection, delivery, and monitoring; the trial is not an instruction for self-administration.

Source: EMA · Prialt overview ↗

Identity, route, and evidence limits

The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.

Source: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Official product context · checked October 4, 2026

EMA describes confusion, memory impairment, dizziness, and other neurological effects among reported adverse reactions. Specialist delivery and the full product precautions are essential to interpreting its benefits.

Source: EMA · Prialt authorization and product overview ↗

Regulatory status

U.S. FDA approval
Approved
Prialt intrathecal infusion (NDA 021060, approved December 2004) for severe chronic pain. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Medicine status & clinical context

EMA describes Prialt as an authorized medicine for severe chronic pain requiring intrathecal analgesia. This is a specialist pain-treatment context; an authorization for a particular medicine is not approval of a supplier’s preparation.

The selected trial studied refractory pain in patients with cancer or AIDS. EMA’s Prialt information provides the product context; specialist administration and product-specific precautions matter.

Source: EMA · Prialt authorization and product overview ↗

Source: EMA · Prialt overview ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

How Ziconotide works

Blocking N-type calcium channels modifies pain-signal transmission. The route is part of the intervention: delivery into spinal fluid is different from a skin or muscle injection.

Source: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Molecular structure

Ziconotide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16135415 ↗

Questions worth asking

  • Does this establish a general-purpose pain peptide?
  • What population, comparator, and route were actually studied?
  • The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Does this establish a general-purpose pain peptide?

No. The trial concerns a particular medicine, intrathecal route, and refractory-pain population. Those findings cannot be transferred to an unrelated preparation or route.

Source: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗

Does the official medicine reference cover every use discussed online?

No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.

Source: EMA · Prialt authorization and product overview ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Ziconotide

Download illustration ↓Source record ↗
Ziconotide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.